Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and GLP-1 receptor agonists in earlier lines of treatment is increasing. GLP-1 and GIP / GLP-1 receptor agonists offer excellent glucose-lowering and weight-loss benefits in once-weekly and oral forms, making them highly attractive options for patients and physicians alike. The late-phase pipeline mainly comprises drugs from established drug classes, including GLP-1 receptor agonists, long-acting insulin / GLP-1 receptor agonist FDCs, and SGLT-2 inhibitors. We expect the entry of therapies with more convenient dosing options to further boost the market throughout the 2024-2034 forecast period. In this report, we explore how unmet needs, pricing, coverage, and regulatory reforms in China will impact the success of current and future players in this highly lucrative market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable T2D population, and how will drug-treatment rates change during the forecast period?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of T2D in China?
- What are the key market access considerations, and how will they affect the uptake of emerging therapies for T2D in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events.
Primary Research
Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 endocrinologists in China
Epidemiology
Diagnosed prevalence of type 2 diabetes patients in urban versus rural China: clinically relevant and commercially relevant drug-treatable populations
Forecast
10-year, annualized, drug-level sales and patient share of key type 2 diabetes therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions
Drug treatments
Coverage of key current and late-phase emerging therapies
Custom drug modeler
Integrated tool to input customized forecast assumptions (e.g., launch date, price)
